AXE

About AXE

Archer Materials Limited (AXE) is a technology company with a focus on developing deep tech in the semiconductor industry. The Group is developing and working towards commercialising semiconductor devices and sensors relevant to quantum computing, TMR sensors and lab-on-a-chip medical diagnostics.

Find out what a historical investment in Archer Materials would be worth today using our AXE stock calculator.

What does Archer Materials do?

Archer wants to power the next generation of computing.

Founded in 2007 and headquartered in Adelaide, Archer Materials Limited is an Australian materials technology company. It specialises in the development of advanced semiconductor devices and processor chips related to quantum computing and medical diagnostics in Australia. 

The company is currently developing its 12CQ qubit processor chip at The University of Sydney to amplify the next generation of high-powered quantum computers. The aim with 12CQ qubit chips is to have them operate at room temperature so they can be integrated into modern electronics.

Archer Materials is also focused on developing its A1 biochip. The ‘lab-on-a-chip’ technology utilises graphene “to provide an ultrasensitive biochemical interface for multi-disease detection and compatibility with digitised processing for biosensor device integration.” Put more simply, the A1 biochip is being developed to detect and analyse diseases.

The A1 biochip is in an earlier stage of development than the 12CQ but the company’s aims for the A1 are no less ambitious as it seeks to make healthcare “cheaper, more efficient and accessible.”

Does Archer Materials have patents on its technology?

As the 12CQ qubit processor chip would be a world-first, Archer Materials is actively chasing patents around the globe. The company has already been granted patents on the 12CQ chip in Japan, South Korea, China, Europe and the United States. The company is working through patent applications for the 12CQ chip in Hong Kong and Australia.

As for the A1 biochip, Archer Materials own 100% of the intellectual property and has filed for an Australian provisional patent application. The company is also trying to progress its A1 biochip patent application in the United States.

How does Archer Materials make money?

The company does not make money at this time. It has stated:

“The Company does not receive any revenue from its operating business and the Company is reliant on capital raisings and the sale of non-core assets to fund its future operations. Therefore, the Company’s ability to continue to develop its technology is contingent upon the Company’s ability to source timely access to additional funding as it is required.”

The first half of FY2022 resulted in a net loss of A$3.23m but via share placements, a share purchase plan to shareholders, exercise of unlisted options, receipt of tax incentives and the sale of plant and equipment, the company’s net cash rose from A$6.93m to A$29.1m.

Archer Materials also has no corporate debt.

Is AXE stock a buy?

Some investors recently got bullish. On 31 March 2022, the company announced that it had overcome “an important step” in enabling its A1 biochip technology to detect and analyse diseases. In the company’s words, “it had successfully integrated a single-atom-'thick' sheet of graphene with silicon electronics.”

AXE stock price leapt over 11% on the same day.

While the latest news is positive, the company has also stated there are still “significant technological challenges to potentially commercialising lab-on-a-chip devices.” Some investors dismiss Archer materials as a speculative investment and cite a weak financial position as a reason not to buy.

Does AXE stock pay dividends?

No. AXE stock has not paid dividends in the past. The company has also not made any announcements to pay dividends in the future.

Who owns AXE stock?

At 84.7% of the total float, the general public owns an overwhelming majority of AXE stock.

Individuals also own a substantial amount of AXE at 10.5% of the total float. Some of these individuals include former Non-Executive Director Dr Alice McCleary (1.56%), Executive Chairman Gregory English (1.42%), Roger Koch (1.13%) and CEO Dr Mohammad Choucair (1.05%).

Other substantial stockholders include Dragon Mining Limited (3.04%), Kooyap Pty Ltd (0.76%) and Clockwell Pty. Ltd (0.42%).

How do I buy AXE stock?

Stake offers a quick and easy way to purchase AXE shares – along with 2,000+ other Australian stocks and ASX ETFs – for a brokerage fee of only A$3.

Stake is a CHESS sponsored investing platform, meaning that when you buy ASX shares, you get a HIN (Holder Identification Number) and stocks are held in your name.

With Stake, you can be in the market in under 5 minutes, whether it's the ASX or Wall St. If you’re interested in building your portfolio by adding AXE, sign up today.